About: http://data.cimple.eu/news-article/06aa254e532f9278de425330d3536b5173d46f7a9949b0ff59c8209e

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/06aa254e532f9278de425330d3536b5173d46f7a9949b0ff59c8209e Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pfizer and BioNTech said Wednesday that a completed study of their experimental Covid-19 vaccine showed it was 95 percent effective. They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators "within days." The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe. "The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," said Pfizer CEO Albert Bourla. "With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," he added. Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective. On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis. Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November. The FDA had imposed a requirement on Covid-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe. Moderna developed its vaccine along with the US National Institutes for Health. Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus. This trains the immune system to be ready to attack if it encounters SARS-CoV-2. Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose. No mRNA vaccines have ever been approved, but Anthony Fauci, the United States' top infectious disease scientist, told AFP Tuesday the technology had now "established itself." dw/adp
schema:headline	Pfizer/BioNTech say final results show vaccine 95% effective
schema:mentions	Adenosine triphosphate Emergency Use Authorization Lysergic acid diethylamide USA Gymnastics Infection Johnson & Johnson Protein University of Oxford Immune system AstraZeneca Anthony S. Fauci Food and Drug Administration Messenger RNA Chief executive officer Pandemic Virus Pfizer Vaccine United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Data warehouse Alpha-fetoprotein
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-11-18 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	81 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software